Erasca's Naporafenib receives FDA Fast Track Designation in combination with Trametinib (Mekinist) for the treatment of adult patients with advanced NRAS-mutated melanoma. Naporafenib has been dosed in over 500 patients to date, and has demonstrated preliminary evidence of its effectiveness. Naporafenib (LXH254) is an orally available pan-RAF inhibitor under development. It targets downstream BRAF and CRAF nodes, and has first-in-class and best-in-class potential in NRAS-mutated melanoma and other RAS/MAPK pathway-altered solid tumors.
Поиск 
+86 21 5895 0110 
